Abstracts by keywords: psoriasis vulgaris
There are a variety of treatment options available to treat psoriasis vulgaris. The S3 guideline of the AWMF defines the current standard of treatment. As early as 2005, a Germany-wide study pointed to an undersupply of psoriasis vulgaris. A variety of treatment options are available to treat psoriasis vulgaris. The S3 guideline of the AWMF defines the current standard of treatment. As early as 2005, a Germany-wide study pointed to an undersupply. In the present Germany-wide cross-sectional study, the care situation of patients with psoriasis in Germany was examined in 2007. The following characteristics, among others, were recorded in 142 dermatological practices and clinics: a) Doctor questionnaire: previous therapies and illnesses, clinical characteristics, severity level (PASI), b) Patient questionnaire: quality of life, patient-relevant therapy benefits, satisfaction with care. Eight indicators of the quality of care were developed in an expert consensus. 11.6 % of the 2,009 patients had severe (PASI>20) and 27.4 % had moderate psoriasis (PASI 10-20). The mean PASI was 10.1. 32.2 % of the patients indicated a severely impaired quality of life (DLQI>10), the mean DLQI was 7.5. Almost half (47.3 %) of the patients had already received systemic therapy, among those with severe psoriasis 62.1 %. 20.1 % of the patients had been treated as inpatients in the previous year. On average, the patients were unable to work for 3.4 days per year due to their psoriasis. An improvement in the quality of care compared to 2005 could be seen in all eight indicators. In the present Germany-wide cross-sectional study, the care situation of patients with psoriasis in Germany was examined in 2007. The following characteristics, among others, were recorded in 142 dermatological practices and clinics: a) Doctor questionnaire: previous therapies and illnesses, clinical characteristics, severity level (PASI), b) Patient questionnaire: quality of life, patient-relevant therapy benefits, satisfaction with care. Eight indicators of the quality of care were developed in an expert consensus. 11.6 % of the 2,009 patients had severe (PASI>20) and 27.4 % had moderate psoriasis (PASI 10-20). The mean PASI was 10.1. 32.2 % of the patients reported a severely impaired quality of life (DLQI>10), the mean DLQI was 7.5. Almost half (47.3 %) of the patients had already received systemic therapy, among those with severe psoriasis 62.1 %. 20.1 % of the patients had been treated as inpatients in the previous year. On average, the patients were unable to work for 3.4 days per year due to their psoriasis. An improvement in the quality of care compared to 2005 could be seen in all eight indicators.